Navigation Links
MicroRNAs can be tumor suppressors

University of Virginia researchers have discovered that microRNAs, a form of genetic material, can function as tumor suppressors in laboratory studies.

In the May 1 issue of Genes & Development, UVa researchers Drs. Yong Sun Lee and Anindya Dutta have shown that microRNAs can suppress the overexpression of a gene called HMGA2. This gene is related to creation of fatty tissue and certain tumors, as well as diet-induced obesity.

MicroRNA is a single-stranded RNA that is typically only 20-25 nucleotides long and is related to regulating the expression of other genes.

"Overexpression of the HMGA2 gene is an essential feature of many medically significant tumors, such as uterine fibroids,?explains Dr. Dutta. “It is very exciting to realize that microRNAs have an important role in suppressing the overexpression of HMGA2. Thus, they may also have a role in causing, and perhaps curing, a disease that is responsible for the vast majority of hysterectomies in the Western world."

Studying chromosomal HMGA2 translocations that are associated with human tumors, the researchers found that, in normal cells, a microRNA called let-7 binds to the 3?end of the HMGA2 mRNA transcript and suppresses its expression in the cell cytosol. However, chromosomal breaks that shorten the 3?end of the HMGA2 transcript,and prevent let-7 binding, result in aberrantly high levels of HMGA2 expression and tumorigenesis (formation of tumors).

This paper establishes that HMGA2 is a target of let-7, and that the let-7 microRNA functions as a tumor suppressor to prevent cancer formation in healthy cells.


'"/>

Source:University of Virginia Health System


Page: 1

Related biology news :

1. MicroRNAs play a big part in gene regulation - and evolution
2. MicroRNAs have shaped the evolution of the majority of mammalian genes
3. MicroRNAs as tumor suppressors
4. Mouse brain tumors mimic those in human genetic disorder
5. Researchers add new tool to tumor-treatment arsenal
6. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
7. Pulsating ultrasound enhances gene therapy for tumors
8. Scientists identify molecule that regulates well-known tumor suppressor
9. New tumor-suppressor gene discovered
10. NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses
11. Natural tumor suppressor in body discovered by UCSD medical researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MicroRNAs can tumor suppressors

(Date:7/30/2014)... ALBANY, New York , July 30, 2014 ... up-to-date research on Global Government Biometric Systems ... Analysis. The Global Biometric Systems Market ... global biometric systems market over the next ten ... industry, using detailed market size forecasts. ...
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... interest in neuroscience. A large number of genes ... Wallerian degeneration: transcription factor activation, immune response, myelin ... in the distal segment of the sciatic nerve ... gene expression between the proximal and distal segments ... Nantong University, China used microarrays to analyze changes ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... trauma, say from a sabertooth tiger attack, meant immediate death ... to survive severe injury caused by a car crash, gunshot ... does not know what to do when it survives an ... evolution. Nearly one third of the time, mechanisms in place ...
... that the ability of plants to defend themselves by accumulating ... some insects, and that such adaptation potentially echoes in the ... evolve to deal with high levels of the toxic element. ... and colleagues there and at the University of California, Berkeley, ...
... and proteins that explain how animals discern bitter from sweet, ... mutant fruit flies prefer eating sugar over sugar laced with ... that a single protein missing from the fly-equivalent of our ... the caffeine as if it were not there. , "No, ...
Cached Biology News:PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 3
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Group (USA), Inc. (the "Company" or "Tiens", NYSE AMEX: ... announced financial results for the third quarter and nine months ... of 2010 was $10.4 million, compared to $9.4 million for the ... 30, 2010 was $30.0 million, compared to $48.2 million for the ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
... Webcast to Discuss ASSERT Clinical Trial Data ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 2Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 3Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 5Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 6Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 7
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
...
... the revolutionary Luminex 100 System delivers a ... real time enhancing your operational efficiency. This ... Luminex 100, the XY Platform, and the ... you to simultaneously assay up to 100 ...
Biology Products: